Open AccessPB2138: VITALIZE TRIAL: A PHASE 2B, OPEN‐LABEL, MULTICENTER, RANDOMIZED PARALLEL‐GROUP, TWO‐STAGE, STUDY OF MAVEROPEPIMUT‐S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW‐DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
Author(s) -
Lee E.,
Matasar M.,
Conlon R.,
Mody K.,
Fiset S.,
Graff J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851384.52638.ca
Subject(s) - medicine , pembrolizumab , oncology , regimen , cyclophosphamide , lymphoma , refractory (planetary science) , phases of clinical research , clinical trial , chemotherapy , cancer , surgery , immunotherapy , physics , astrobiology